private:archbiopartners
|
8449048
|
May 22nd, 2019 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB)
|
66
|
1.00
|
Open
|
Biotechnology
|
May 22nd, 2019 09:14AM
|
May 22nd, 2019 09:14AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance select pre-clinical technologies and develop the most promising medical inventions and therapeutics.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
Open
|
New drugs to treat gram -negative bacterial infections, Sepsis and Cancer Metastasis, Inhibiting corrosion, biofilm on metals and plastics, Treating Acute Kidney Injury
|
Open
|
27 St. Clair Ave East, PO Box 305
|
Toronto
|
ON
|
CA
|
M4T 2M5
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Mar 23rd, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Mar 23rd, 2017 10:51AM
|
Mar 23rd, 2017 10:51AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 17th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 16th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 15th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 14th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 13th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 12th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 11th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|
private:archbiopartners
|
8449048
|
Feb 10th, 2018 12:00AM
|
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCBB)
|
39
|
3.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
|
|
|
|
|
|
|
|
|
|
Arch Biopartners
|
|
Health Care Equipment & Services
|